Prime Medicine Inc (NASDAQ:PRME) has a beta value of 2.15 and has seen 2.57 million shares traded in the last trading session. The company, currently valued at $182.31M, closed the last trade at $1.39 per share which meant it gained $0.15 on the day or 12.10% during that session. The PRME stock price is -494.96% off its 52-week high price of $8.27 and 19.42% above the 52-week low of $1.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.7 million shares traded. The 3-month trading volume is 1.31 million shares.
The consensus among analysts is that Prime Medicine Inc (PRME) is Buy stock at the moment, with a recommendation rating of 1.18. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
Sporting 12.10% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PRME stock price touched $1.39 or saw a rise of 10.32%. Year-to-date, Prime Medicine Inc shares have moved -52.40%, while the 5-day performance has seen it change 4.51%. Over the past 30 days, the shares of Prime Medicine Inc (NASDAQ:PRME) have changed -30.85%. Short interest in the company has seen 18.3 million shares shorted with days to cover at 12.39.
Wall Street analysts have a consensus price target for the stock at $17, which means that the shares’ value could jump 91.82% from current levels. The projected low price target is $12.0 while the price target rests at a high of $23.0. In that case, then, we find that the current price level is -1554.68% off the targeted high while a plunge would see the stock gain -763.31% from current levels.
Prime Medicine Inc (PRME) estimates and forecasts
The company’s shares have lost -64.90% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 560.21%.
9 analysts offering their estimates for the company have set an average revenue estimate of 3.43M for the current quarter. 9 have an estimated revenue figure of 3.39M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -124.13% over the past 5 years. Earnings growth for 2025 is a modest 27.26% while over the next 5 years, the company’s earnings are expected to increase by 12.59%.
PRME Dividends
Prime Medicine Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders own 23.91% of the company shares, while shares held by institutions stand at 59.10% with a share float percentage of 77.67%. Investors are also buoyed by the number of investors in a company, with Prime Medicine Inc having a total of 172.0 institutions that hold shares in the company. The top two institutional holders are ALPHABET INC. with over 15.06 million shares worth more than $77.42 million. As of 2024-06-30, ALPHABET INC. held 12.6375% of shares outstanding.
The other major institutional holder is ARK INVESTMENT MANAGEMENT LLC, with the holding of over 6.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $31.49 million and represent 5.1404% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.91% shares in the company for having 2.5 shares of worth $3.47 million while later fund manager owns 2.1 shares of worth $2.91 million as of Dec 31, 2024 , which makes it owner of about 1.60% of company’s outstanding stock.
